Rybodyn
1 known investors
RyboDyn develops immunotherapies by using its RyboCypher platform, which combines RNA sequencing with AI models trained on proprietary transcriptomic and proteomic databases to identify proteins encoded by supposedly non-coding regions of the genome (the "dark proteome"). The company turns these newly identified targets into a pipeline of antibody-based drug candidates aimed at unmet needs in cancer and disease treatment.